BridgeBio Pharma Announces Updated Phase 2B Data for Encaleret in Autosomal Dominant Hypocalcemia Type 1 (ADH1) Demonstrating Blood and Urine Calcium Normalization in Trial Participants

/PRNewswire/ -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company founded to discover, create, test and deliver meaningful...

Related Keywords

San Diego ,California ,United States ,American ,Jonathan Fox ,Katherine Yau ,Jocelyn Ashford ,Rachel Gafni ,Linkedin ,Senior Research Physician ,Twitter ,Nasdaq ,Bridgebio Pharma Inc ,European Union ,National Institutes Of Bio ,Craniofacial Research ,Pamerican Society For Bone ,National Institutes Of Health ,Drug Administration ,Exchange Commission ,Securities Exchange ,Bio Pharma Inc ,Mineral Research ,Bio Pharma ,Autosomal Dominant Hypocalcemia Type ,Mineral Physiology ,Demonstrate Proof Of Concept ,Yearly Results ,Ongoing Phase ,Dose Ranging Study ,American Society ,Mineral Homeostasis Studies Group ,National Institute ,National Institutes ,Chief Medical Officer ,Molybdenum Cofactor Deficiency ,Fast Track ,Orphan Drug Designations ,Bridgebio Pharma ,Securities Act ,Securities Exchange Act ,Exchange Act ,Risk Factors ,Amer Jour ,Hum Genetics ,Bio Media Contact ,Bio Investor Contact ,Advocacy Contact ,Bridgebio ,Health Care Amp Hospitals ,Medical Pharmaceuticals ,Biotechnology ,Clinical Trials Amp Medical Discoveries ,